Business Context and Reporting Period
Cytosorbents Corp filed a Form 8-K on January 9, 2015, reporting the entry into a material definitive agreement. The filing details a public offering of common stock that closed on January 14, 2015, with the registration statement becoming effective on January 9, 2015.
Key Financial Metrics
- Shares Issued: 1,250,000 shares of common stock.
- Offering Price: $8.25 per share.
- Net Proceeds: Approximately $9.48 million after deducting underwriting discounts, commissions, and offering expenses.
- Warrants Issued: Warrants to purchase up to 37,500 shares issued to underwriters (representing 3% of the offering).
- Warrant Terms: Exercisable within five years at $9.90 per share (120% of the public offering price).
The filing does not provide data on revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in equity capital and share count resulting from the underwritten public offering. The company raised approximately $9.48 million in net proceeds, significantly impacting its liquidity position compared to the pre-offering period.
Outlook, Risks, and Management Commentary
Management announced the closing of the offering via a press release dated January 14, 2015. The filing does not contain specific forward-looking guidance, risk factors, or discussion of contingencies beyond the standard terms of the underwriting agreement.
Investor Verification Checklist
- Verify the final closing date and actual share count issued (reported as January 14, 2015).
- Confirm the exact net proceeds received after all final legal fees and expenses.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific indemnification or lock-up provisions.
- Check subsequent filings for the use of proceeds and any dilution impact on existing shareholders.